Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Knowing when a retirement plan outperforms a 401k can significantly influence your retirement strategy. Find out the critical factors to consider.
27,035 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
July can be a pivotal moment for travel stocks. Here are three clear reasons why Carnival stock may deserve a place o...
As the auto industry pivots to software and batteries, investors must pick between a giant with scale and a high-grow...
Micron's latest quarterly results delivered a powerful reset for MU, but the stock's next move remains uncertain. Thi...
As Home Depot gears up to report, investors weigh EPS targets, margin dynamics, and housing trends. This guide breaks...
Insider transactions can reveal confidence or caution. This guide digs into ultra clean insider sells, what they sign...
IP Strategy said its board approved a buyback of up to 1,000,000 common shares through Dec. 31, 2026, potentially tri...
The 2026 multifamily crash reshapes how lenders and sponsors think about risk and return. This guide explains what we...
SpaceX IPO plans could redefine the space economy, but Blue Origin is positioned to challenge. Learn how to evaluate ...
When a top investor steps up after a steep drop, it signals conviction. This deep dive looks at why First Beijing bou...
When a prominent fund makes a sizable stake reduction, it often signals more than profit-taking. This article breaks ...
IBM is capturing attention this week with a blend of quantum computing momentum and AI-powered cybersecurity initiati...